AOBO to launch Yin Yang balancing medication Pai Du Qing Zhi Tablet

NewsGuard 100/100 Score

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that its Boke brand Pai Du Qing Zhi Tablet, ("PDQZ Tablet"), a prescription medicine aimed at achieving the balance of Yin Yang by regulating metabolism, in order to cleanse the blood and detoxify, dispose of hemorrhoids, fight obesity and lower hyperlipemia, will be commercially launched in the third quarter of 2010. The Company completed successful test marketing in the second quarter of 2010.

The Company will launch the PDQZ Tablet under its well-established Boke brand to leverage market recognition for the brand. Boke, a wholly owned subsidiary of the Company, has become a recognized and trusted brand through the popularity and increasing sales of its all-natural Boke Nasal Spray. Like Boke Nasal Spray, Boke PDQZ Tablet will also be formulated from all natural ingredients, such as botanical extractions and excipients.

Mr. Tony Liu commented, "The successful launch of the PDQZ Tablet marks a milestone for our R&D team. We believe this milestone marks only the beginning of many future success projects to come."

Source:

American Oriental Bioengineering, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk